Aktienanalyse zu Cue Biopharma Inc (CUE)CUECue Biopharma Inc

Cue Biopharma, Inc. is a clinical-stage biopharmaceutical company, developing a novel class of injectable biologics to selectively engage and modulate disease-specific T cells directly within the patient’s body. Its proprietary platform, Immuno-STAT (Selective Targeting and Alteration of T cells) and biologics are designed to harness the curative potential of the body’s intrinsic immune system through the selective modulation of disease-specific T cells without the adverse effects of broad systemic immune modulation. Its lead programs include drug product candidates designed to: CUE-400 series (Autoimmune Diseases) enhance regulatory T cells (Tregs) with a novel mechanism to proliferate, generate Tregs, and restore immune balance (CUE-401 for autoimmune conditions);CUE-500 series (Targeted Cell Depletion) redirect antiviral T cells to target eliminate pathogenic cells (CUE-501 for autoimmune B cell depletion); and CUE-100 series (Oncology) selectively activate tumor-specific T cells. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Cue Biopharma Inc is a good buy right now due to its recent positive Phase 2a trial results for CUE-221, which showed a 54% complete hive resolution rate compared to 11% for placebo. Additionally, the stock is currently priced at $19.42, significantly below the analyst target of $83, indicating substantial upside potential. However, the company reported a net loss of $153.07 million in Q2 2026, which poses a risk to its financial stability.

1 analysts cover CUE: 1 rate it Buy, 0 Hold and 0 Sell.